Benefits of the ras blockade: Clinical evidence before the ontarget study

Journal of Hypertension

Volumn 27, Issue SUPPL. 2, 2009, Pages

  Perret Guillaume, Christine ^a   Joly, Laure ^a   Jankowski, Piotr ^b   Benetos, Athanase ^a  

^a Medical School of Nancy   (France)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Cardiovascular risk; Renin?angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTERIAL STIFFNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; METABOLIC DISORDER; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENAL DIABETES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; METABOLIC SYNDROME X; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; RENIN-ANGIOTENSIN SYSTEM;

EID: 69449093875     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000354511.14086.f1     Document Type: Review

References (44)

1. Wang M, Takagi G, Asai K, Resuello RG, Natividad FF, Vatner DE, et al. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 2003; 41:1308-1316.
2. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part III: Cellular and molecular clues to heart and arterial aging. Circulation 2003; 107:490-497.
3. Yusuf S, Sleight P, Pogue J, Davies R, Dagenais G. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
4. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
5. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98:121-128.
6. Galderisi M, de Divitiis O. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 2008; 51:523-531.
7. Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73:237-246.
8. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leucocytes, nuclear factor-kappa [beta], in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003; 88:4496-4501.
9. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-1659.
10. Ikejima H, Imanishi T, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, et al. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hypertens 2008; 26:964-972.
11. Durier S, Fassot C, Laurent S, Boutouyrie P, Couetil J, Fine E, et al. Physiological genomics of human arteries; quantitative relationship between gene expression and arterial stiffness. Circulation 2003; 108:1845-1851.
12. Safar ME, Benetos A. Factors influencing arterial stiffness in systolic hypertension in the elderly: role of sodium and renin-angiotensin system. Am J Hypertens 2003; 16:249-258.
13. Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R, Poirier O, et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996; 94:698-703. (Pubitemid 26289224)
14. Lajemi M, Labat C, Gautier S, Lacolley P, Safar M, Asmar R, et al. Angiotensin II type 1 receptor ~153A/G and 1166A/C gene polymorphisms and increased aortic stiffness with age in hypertensive subjects. J Hypertens 2001; 19:407-413.
15. Balkenstein EJ, Staessen JA, Wang JG, van der Heijden-Spek JJ, van Bortel LM, Barlassina C, et al. Carotid and femoral artery stiffness in relation to three candidate genes in a white population. Hypertension 2001; 38:1190-1197.
16. Staessen Ja, Wang JG, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003; 361:1629-1641.
17. Mattace-Raso F, van der Cammen T, Sayed-Tabatabei F, van Popele N, Asmar R, Schalekamp A, et al. Angiotensin-converting enzyme gene polymorphism and common carotid stiffness. The Rotterdam Study. Athersclerosis 2004; 174:121-126.
18. Benetos A, Levy B, Lacolley P, Taillard F, Duriez M, Safar ME. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17:3196-3201.
19. Labat C, Lacolley P, Lajemi M, De Gasparo M, Safar ME, Benetos A. Effects of valsartan on mechanical properties of the carotid artery in SHR under high salt diet. Hypertension 2001; 38:439-443.
20. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al., CAFE Investigators. Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
21. Cockcroft JR. ACE inhibition in hypertension: focus on perindopril. Am J Cardiovasc Drugs 2007; 7:303-317.
22. Mallareddy M, Parikh CR, Peixoto AJ. Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis. J Clin Hypertens 2006; 8:398-403.
23. Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R. Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens 2002; 15:1087-1091.
24. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE. AT1-receptor blockade improves augmentation index a double-blind, randomized, controlled study. J Hypertens 2002; 20:2423-2428.
25. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99:1006-1012.
26. Tikellis C, Cooper ME, Thomas MC. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int J Biochem Cell Biol 2006; 38:737-751.
27. Benson SC, Pershadsingh HA, HoCI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43:993-1002.
28. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 2005; 16:3081-3091.
29. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
30. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878. (Pubitemid 34940826)
31. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869. (Pubitemid 34940825)
32. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
33. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, De Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16:895-899.
34. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 2008; 21:464-470.
35. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
36. Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan B, Tanser P, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 2004; 43:2200-2206.
37. Brilla CG, Rupp H, Maisch B. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz 2003; 28:744-753.
38. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular. The SOLVD Investigators. N Engl J Med 1991; 325:293-302.
39. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766. (Pubitemid 37093915)
40. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832-1839.
41. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27:512-518.
42. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC Jr, Kasi VS. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004; 165:1019-1032.
43. Kasi VS, Xiao HD, Shang LL, Iravanian S, Langberg J, Witham EA. Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation. Am J Physiol Heart Circ Physiol 2007; 293:H182-H192.
44. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719.